Vascular Access Complications for Therapeutic Apheresis in Nephrology

Vascular Access Complications for Therapeutic Apheresis in Nephrology : a Retrospective Observational Study in North-East France.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05894317

Acronym

VACTANE

Enrollment

Registered

2023-06-08

Start date

2020-06-01

Completion date

2025-02-14

Last updated

2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apheresis Related Complication, Vascular Access Complication

Keywords

Apheresis, DFPP, ANCA associated vasculitis, Goodpasture syndrome, Arterio veinous fistula, Arterio veinous graft

Brief summary

The aim of this study is to describe vascular access complications which are used for therapeutic apheresis in Nephrology.

Detailed description

The aim of this study is to describe vascular access complications which are used for therapeutic apheresis in Nephrology. Complications may include arterio-veinous fistula or graft (AVF or AVG) thrombosis with or without known stenosis; AVF or AVG or central veinous catheter (CVC) infections and CVC dysfunctions. The investigators may enroll all patients receveing therapeutic apheresis for nephrologic indications in North East France. Nephrologics indications include : * acute or active antibody mediated rejection (ABMR), * Goodpasture disease, * ANCA vasculitis, * thrombotic microangiopathy (TMA), * Focal segmental glomerulosclerosis (FSGS), * HLA or ABO desensitization for kidney transplantation. Data inclusion period is from June 2020 to June 2022. The aim of the study is to describe the proportion and type of complication in the population of patient receving therapeutic apheresis for nephrologic disease in the North East France. Te investigators will study the risk factors that are associated with this complications. The second aim of the study is to describe the population of patient receving therapeutic apheresis in our unit and in our region.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* patients in nephrology receiveing apheresis treatment by filtration or double filtration

Exclusion criteria

* apheresis treatment for other indications * centrifugation apheresis treatment

Design outcomes

Primary

Measure	Time frame	Description
Vascular access Complication (catheter or AVF/AVG thrombosis/infection) rate in therapeutic apheresis among nephrological diseases	june 2020 june 2022	Percent of patient with Vascular access Complication

Secondary

Measure	Time frame	Description
Description of population enrolled	june 2020 june 2022	Description of population treated by therapeutic apheresis in Northeast France
Comparison of complications rate with literature datas	june 2020 june 2022	—

Countries

France

Outcome results